Ascentage Pharma
↗Suzhou, China
Ascentage Pharma is a global, integrated biopharmaceutical company focused on discovering, developing, and commercializing first- and best-in-class therapies for cancers, chronic hepatitis B, and age-related diseases. The company specializes in targeting protein-protein interactions to restore apoptosis (programmed cell death), utilizing a proprietary drug discovery platform.
Headquartered in Suzhou, China, with significant operations in Rockville, Maryland, the company is publicly traded on both the Hong Kong Stock Exchange (6855.HK) and the NASDAQ (AAPG). Ascentage maintains a robust clinical pipeline of small molecule and degrader therapies, with multiple registrational trials ongoing globally.
CLASSIFICATION
SIZE & FINANCIALS
Employees:51-200
Revenue:$100M-$150M
Founded:2009
Ownership:public
Status:operating
FUNDING
Stage:Public
Total Raised:$417M
Investors:Takeda
STOCK
Exchange:NASDAQ, HKEX
Ticker:AAPG, 6855
Market Cap:$2.33B
PIPELINE
Stage:Commercial
Lead Drug Stage:Commercial
Modalities:Small molecule, PROTAC, Tyrosine kinase inhibitors
Active Trials:40
Trial Phases:Phase 1: 20 | Phase 2: 15 | Phase 3: 5
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Subsidiaries:Ascentage Pharma (Suzhou) Co. Ltd.
Key Partnerships:Takeda (exclusive option for Olverembatinib), Innovent Biologics (joint commercialization in China)
COMPETITION
Position:Emerging
Competitors:AbbVie, Genentech, Novartis
LEADERSHIP
Key Executives:
Edward Ming Guo - Co-Founder
Scientific Founders:Shaomeng Wang
LINKS
Website:ascentage.com
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Ascentage Pharma and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Ascentage Pharma. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.